China+1 moment for pharma: How India can convert opportunity into long-term contracts
The global healthcare industry has long relied on China for the majority of its active ingredients, APIs, and chemicals, making…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Guest Blogs
Navigating legal and regulatory landscape of GLP-1 drugs in India
India is currently facing a growing public health issue, with recent data showing that nearly a quarter of the adult population is…
The cosmetic-medicine grey zone
Prof Dr Debraj Shome, Clinical Scientist and Research Mentor, QR678 opines that when molecules with known biological action are…
Tariffs & sustainability: Why Indian pharma can no longer treat them as separate conversations
For a long time, Indian pharmaceutical companies could treat trade policy as a background variable. The real focus in the last…
India’s counterfeit drug crisis and the role of AI
India is facing a perilous rise in counterfeit high-value medicines, from cancer immunotherapies like Keytruda (pembrolizumab) to…
Patent pause: Link extensions to pendency
India is now well-positioned to introduce a limited, risk-calibrated patent-term extension (PTE) mechanism tailored to Active…
An emerging disruption in drug traceability for India and beyond
Avi Chaudhuri, PhD, Founder, The Kulinda Consortium reviews the challenges of drug traceability and new approaches being developed…
Powering India’s biologics future: Industry-academia partnerships as the engine of growth
In just a decade, India’s bioeconomy has expanded from USD 10 billion in 2014 to over USD 165 billion in 2024, now contributing…
Next phase of growth: The case for innovation-led pharma organisations in India
Growth in India’s pharmaceutical industry is entering a more demanding phase, where existing methods are beginning to become less…
Phytopharmaceuticals in India: A case for perpetual ‘New Drug’-style regulation over ASU-style…
Introduction
Phytopharmaceuticals in India: Bridging Tradition, Science and “New Drug”-Style Regulation
Setting the stage…
Off label drug use and physician liability
Dr Amit Kumar, Assistant Professor of Law, Maharashtra National Law University Mumbai, examines the complex legal and ethical…
India’s biopharma moment—If we get the ecosystem right
Krishna Sarma highlights the ecosystem requirements for advancing biopharma innovation in India
Clinical exclusivity for indigenous medicines can improve long-term affordability and access
Nikkhil Masurkar, CEO, Entod Pharmaceuticals opines that in the absence of clinical data exclusivity, competitors may obtain…
The GLP-1 revolution
A new class of drugs is reshaping global health,but India’s generics wave could change who benefits. Dr Rajpushpa Labh,Consultant…
India’s opportunity to lead next generation injectable drug innovation
India is rapidly evolving into a global hub for generic injectable drugs, driven by rising disease burden, cost efficient…
The algorithmic inversion of pharma
The century-old model is cracking
For more than a hundred years, pharma innovation followed a reassuringly stable pattern. A…
India’s upcoming semaglutide boom: A turning point for GLP‑1 drugs, pricing and patient access
With semaglutide’s Indian patent set to expire on March 20, 2026, domestic drugmakers are preparing to enter the GLP‑1 market,…
Invisible but indispensable: Why high purity & premium grade refined Naphthalene is critical to…
India’s rise as the pharmaceutical hub of the World is one of the country’s most consequential industrial stories. It is a journey…
Redrawing the biopharma map: India’s rise in the biosimilars era
For India’s biopharma sector, 2025 stood out as an inflection point. The approval of 146 recombinant biosimilar therapeutic…
You do not need to become someone else to lead
On International Women’s Day, Gopa Gayakar reflects on self-doubt, leadership and why women in pharma must trust their voice to…